SEN1500, a novel oral amyloid- β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer’s disease

Discussion SEN1500 is not only able to reduce Aβ pathology and activated microglia but also to improve learning and memory as previously shown, making SEN1500 a potential candidate for human AD treatment. This Aβ aggregation inhibitor could be a promising therapeutic agent for the disease-modifying treatment of AD.
Source: Neuroscience Letters - Category: Neuroscience Source Type: research